UNSPSC 51351613: Mifepristone

This classification denotes an anti-progestin with the molecular formula C29H35NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 320T6RNW1F, chemically known as 17-beta-hydroxy-11-beta-(4-dimethylaminophenyl-1)-17-alpha-(prop-1-ynyl)oestra-4,9-dien-3-one but generally known as mifepristone, which bears US NIH Compound Identifier 55245. European Medicines Agency schedules Mifepristone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08956MIG.

UNSPSC 51351613 Mifepristone, a Commodity code, covers pharmaceutical procurement by state and local health agencies and cooperative purchasing alliances, where recent solicitations seek manufacturers of generic pharmaceuticals and over-the-counter products distributed through authorized wholesale channels to public health systems and facilities. The scope encompasses manufacturers capable of supplying products with full National Drug Codes (NDC), packaging configurations, and manufacturing documentation to support multi-state and multi-facility distribution networks. State and local issuers under this code include state health departments, cooperative purchasing alliances (such as multistate consortia), and subordinate public health facilities served through those alliances. Vendors must demonstrate compliance with current Good Manufacturing Practices (cGMP), the Drug Supply Chain Security Act (DSCSA), and FDA requirements, maintain contractual relationships with authorized wholesalers, and support electronic data interchange (EDI) systems. Insurance requirements typically include commercial general liability of $5,000,000 per occurrence, network security and privacy liability of $2,000,000, and professional liability of $2,000,000.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (Solicitation S1070000015802) on January 20, 2026 to establish multiple contracts for generic pharmaceuticals and OTC products, with proposals due March 26, 2026 and questions due February 18, 2026. The contract is effective July 1, 2026 and spans two years for new responders with optional extensions, while participating jurisdictions include Minnesota and Oregon. Evaluation criteria weighted price competitiveness at 75 percent, with the remaining 25 percent split among fixed pricing (10 percent), compliance with data format and EDI capability (5 percent each), and agreement to a 3 percent administrative fee (5 percent). Products must be available in the marketplace by May 15, 2026, and vendors must supply pricing through AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, or Morris & Dickson Co., LLC. No specific set-aside or disadvantaged-enterprise restrictions apply to this solicitation based on available documentation.